GigaGen Inc., a world leader in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announced that it has achieved all of the technical goals for four Phase I grants from the National Institutes of Health (NIH). The Phase I grants were awarded through the NIH Small Business Innovation Research (SBIR) program in 2015 from the National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Diseases (NIAID). The NIH SBIR program is highly competitive, with <15% of applications receiving funding in most years.

 

Read the full press release.